Heme oxygenase and GCLC can lead to COPD disease aggravation, indicating increasing Nrf2 activity as a treatment strategy in COPD (Digaleh et al., 2013; Niforou et al., 2014; Wu et al., 2015). The gene discussed is GCLC; the disease is chronic obstructive pulmonary disease.